Edition:
United States

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

174.92USD
4:00pm EDT
Change (% chg)

$-2.09 (-1.18%)
Prev Close
$177.01
Open
$176.36
Day's High
$176.49
Day's Low
$174.54
Volume
392,356
Avg. Vol
361,993
52-wk High
$189.39
52-wk Low
$119.37

ILMN.OQ

Chart for ILMN.OQ

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $25,896.56
Shares Outstanding(Mil.): 146.30
Dividend: --
Yield (%): --

Financials

  ILMN.OQ Industry Sector
P/E (TTM): 35.27 44.67 17.37
EPS (TTM): 5.02 -- --
ROI: 19.63 7.68 -5.89
ROE: 32.59 12.62 -5.30

BRIEF-Illumina reports Q1 GAAP earnings per share $2.52

* Illumina reports financial results for first quarter of fiscal year 2017

Apr 25 2017

Illumina, Cornell drop gene sequencing patent dispute

Cornell University and biotechnology company Illumina Inc have dropped a lengthy patent dispute over gene-sequencing technology, citing a "settlement process."

Apr 18 2017

BRIEF-Illumina Inc says CEO Francis A. Desouza's total 2016 compensation was $8.4 mln

* Illumina inc says ceo francis a. Desouza's total 2016 compensation was $8.4 million versus $5.4 million in 2015 - sec filing Source text - http://bit.ly/2ozO37O Further company coverage:

Apr 14 2017

BRIEF-Illumina CEO Francis Desouza's FY 2016 total compensation was $8.4 mln - SEC Filing

* CEO Francis A. Desouza's FY 2016 total compensation was $8.4 million versus $5.4 million in FY 2015 - SEC Filing

Mar 30 2017

BRIEF-Kailos genetics enters into a co-marketing agreement with Illumina

* Illumina will market and promote Kailos Targetrich line of research solutions for pharmacogenetics targets through commercial channels Source text for Eikon: Further company coverage:

Mar 21 2017

Pharma groups file amicus brief in Illumina patent case

Trade groups representing the biotechnology and pharmaceutical industries have asked a federal appeals court to clarify the rules for determining whether arguments not put forth in U.S. Patent and Trademark Office proceedings can be raised later in district court.

Mar 03 2017

BRIEF-Illumina says board increased size of board from 10 to 11 members

* On February 18, 2017, board increased size of board from ten to 11 members and elected John Thompson to board - SEC filing Source text (http://bit.ly/2m4NjYm) Further company coverage:

Feb 21 2017

BRIEF-Illumina says Novaseq's S1, S4 flow cells expected to be available for shipment in Q3 2017

* Illumina Inc- Novaseq's S1 and S4 flow cells have been prioritized and are expected to be available for shipment in Q3 of 2017 - SEC filing

Feb 13 2017

BRIEF-Illumina Q4 non-gaap earnings per share $0.85

* Illumina reports full financial results for fourth quarter and fiscal year 2016

Jan 31 2017

BRIEF-Illumina elects Caroline Dorsa to serve on board

* Illumina Inc - effective as of Jan 26, 2017 increased size of board from nine to ten members and elected Caroline Dorsa to serve on board - SEC filing Source text: (http://bit.ly/2k1ulOq) Further company coverage:

Jan 27 2017

More From Around the Web

Earnings vs. Estimates